Rheumatology Practice Management December 2017 Vol 5 No 6

This study assessed the comparative effectiveness of the Janus kinase1/2 inhibitors, tofacitinib and baricitinib, in patients with rheumatoid arthritis (RA) using a network meta-analysis and Cochrane systematic review of randomized controlled trials from 7 electronic databases and 2 trial registries.

This study explored the effects of sarilumab, an anti–interleukin-6Rα human monoclonal antibody, or placebo in combination with disease-modifying antirheumatic drugs (DMARDs) on fasting glucose and glycosylated hemoglobin (HbA1c) in diabetic and nondiabetic patients with rheumatoid arthritis (RA).

The objective of this post hoc analysis was to assess the proportion of patients who achieved clinical remission or low disease activity (LDA) by week 24 (TARGET) and week 52 (MOBILITY).

The analysis of the COMPACT trial sought to demonstrate noninferiority of tocilizumab alone versus tocilizumab plus methotrexate (MTX) in maintaining clinical response in patients with rheumatoid arthritis (RA) who achieve low disease activity (LDA) following treatment with tocilizumab plus MTX.

San Diego, CA—At the 2017 American College of Rheumatology (ACR) Annual Meeting, Angus Worthing, MD, Arthritis and Rheumatism Associates, Washington, DC, and Chair, ACR Government Affairs Committee, provided a legislative and regulatory update. Discussion topics included ACR contributions on policy development and change, as well as regulatory initiatives currently before Congress and how they may impact rheumatology practices in the future.

In the pivotal MONARCH study, subcutaneous (SC) sarilumab 200 mg plus placebo was administered every 2 weeks (q2w) versus adalimumab 40 mg SC plus placebo q2w.

Using 3 US healthcare claims databases, this population-based cohort study compared the CV risk associated with tocilizumab versus abatacept in patients with RA who newly started tocilizumab (n = 6237) or abatacept (n = 14,685).

Page 3 of 3
Results 21 - 27 of 27
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management